Smart Insulin Pens & Pumps Market (2026 - 2033)

Smart Insulin Pens & Pumps Market Summary

The global smart insulin pens & pumps market size was valued at USD 8.2 billion in 2025 and is projected to grow from USD 9.0 billion in 2026 to USD 17.3 billion by 2033, at a CAGR of 17.2% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 32.0% in 2025. A rising prevalence of diabetes among the young population globally due to increasing adherence to a sedentary lifestyle, growing focus of patients on management and prevention of diabetes, and advancements in healthcare technology are primary factors driving market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Patients with type-1 diabetes and some rare cases with type-2 diabetes require insulin to keep their blood sugar at an optimum level. Continuous innovations in insulin delivery devices, such as improved connectivity, data management capabilities, and enhanced dosing accuracy, have helped drive demand for this market.

The rising incidence of both type 1 and type 2 diabetes is a primary driver of market expansion. According to the International Diabetes Federation (IDF, approximately 589 million adults aged 20–79 years were living with diabetes globally in 2024, accounting for 11.1% of the adult population in this age group. The number of people with diabetes is projected to increase to 853 million by 2050. Increasing global life expectancy has led to a steady rise in the geriatric population, which is contributing to a growth in the number of diabetic patients. As the diabetic population continues to grow in the coming years, the demand for effective and convenient insulin delivery systems is poised to rise.

The growing adoption of digital health technologies among patients has led to increased demand for smart insulin devices that offer convenience, improved adherence, and enhanced self-management capabilities. Smart insulin pens and pumps have proved to be the most sought-after and advanced solutions for diabetic people. The real-time blood sugar monitoring feature allows patients to continuously monitor for hyperglycemia. In addition, these devices administer precise insulin doses compared with traditional injections, which often have dosing issues.

Analyst Perspective

The global smart insulin pens and pumps industry is expected to grow strongly, driven by the rising prevalence of diabetes, increasing awareness of effective disease management, and growing demand for advanced insulin delivery solutions. The integration of smart insulin devices with continuous glucose monitoring (CGM) systems, mobile health applications, and digital diabetes management platforms is transforming insulin therapy by enabling real-time data tracking, personalized dosing recommendations, and improved treatment adherence. Technological advancements, including Bluetooth-enabled connectivity, automated insulin delivery, and AI-powered decision support, are further accelerating market adoption. In addition, favorable reimbursement policies, increasing healthcare expenditure, and the growing shift toward home-based diabetes management are supporting market expansion.

Type Insights

The smart insulin pumps segment led the market with the largest revenue share of exceeding 60.0% in 2025. Insulin pumps offer highly precise insulin delivery by administering a constant flow of the hormone, enabling better glucose control than traditional insulin pens. This is particularly beneficial for patients with Type 1 diabetes and those requiring complex insulin regimens. Moreover, these pumps provide greater flexibility in insulin dosing, allowing for adjustments based on real-time glucose levels and meal intake. This improved convenience contributes to enhanced patient adherence. The ease of dosing and improved glycemic control achieved compared with smart insulin pens drive higher demand for smart insulin pumps, leading to their market dominance.

The smart insulin pens segment is anticipated to grow at a significant CAGR during the forecast period. Insulin pens are more cost-effective than insulin pumps, making them a more accessible option for a broader patient population. Furthermore, insulin pens are more user-friendly and convenient compared to insulin pumps, particularly for patients with less complex diabetes management needs. Their compact size and portability facilitate their easy integration into daily routines. For instance, diabetic patients can carry an insulin pen anywhere during their travels by keeping it in their bags; on the other hand, pumps are attached to the body, making them inconvenient for patients with allergic reactions to pump adhesives and catheters. These factors of affordability and convenience are anticipated to drive steady segment growth.

End Use Insights

The hospitals and clinics segment led the market with the largest revenue share of around 47.0% in 2025. These healthcare facilities serve as primary healthcare delivery centers, thus managing a significant population of diabetic patients requiring insulin therapy. This concentrated patient base requires a continuous supply of insulin-delivery devices. Moreover, hospitals possess the requisite clinical expertise and infrastructure to effectively utilize and manage smart insulin devices. This includes trained medical personnel, advanced monitoring equipment, and established protocols for insulin administration. These factors lead to high demand for insulin delivery solutions in this segment, contributing to its market dominance.

The home care segment is expected to grow at the fastest CAGR from 2026 to 2033. A growing preference for independent disease management has led to a surge in demand for devices that enable patients to monitor and administer their treatments at home. The integration of advanced technologies into smart insulin pens and pumps, such as Bluetooth connectivity for continuous blood sugar monitoring and a dedicated mobile application for accessing health data, has facilitated their increased use in home settings, enhancing patient convenience and compliance. In addition, home care solutions offer a more cost-effective alternative to institutional care, making them increasingly attractive to patients and driving substantial product demand in this segment.

Regional Insights

The smart insulin pens & pumps market in North America accounted for a notable market share in 2025. An increasing number of people suffering from obesity, a growing lack of physical activity among citizens, and an aging population in the region have resulted in a high prevalence of diabetes. The IDF Diabetes Atlas estimated that the North America and Caribbean region had the second highest mortality rate due to diabetes, standing at 14%. Such figures are expected to create a significant market opportunity for modern diabetes-management devices, such as smart insulin pens and pumps.

U.S. Smart Insulin Pens & Pumps Market

The smart insulin pens & pumps market in the U.S. held a significant market share in North America in 2025. According to the American Diabetes Association, around 40 million people in the U.S. suffer from diabetes. The U.S. is home to several prominent pharmaceutical and medical device companies specializing in diabetes care such as Abbott, Insulet Corporation, and Eli Lilly and Company. These industry giants have significantly contributed to the country’s market dominance through product innovation, research, and market penetration.

Europe Smart Insulin Pens & Pumps Market

Europe dominated the global smart insulin pens & pumps market with the largest revenue share of around 32.0% in 2025. Europe possesses a well-developed healthcare infrastructure with significant investments in research and development activities. This has fostered an environment conducive to the adoption of innovative medical technologies, such as smart insulin pens and pumps. Thus, a substantial patient base and high disposable incomes that enable the adoption of innovative solutions create robust demand for smart insulin delivery devices in the region.

To learn more about this report, Download Free Sample Report

The UK smart insulin pens & pumps market accounted for the largest market revenue share in Europe in 2025. The British Diabetic Association (Diabetes UK) estimated that in 2024-25, around 6.0 million people were living with diabetes in the country. Smart insulin pens and pumps have proven effective at controlling high blood sugar levels in patients. The demand for these devices is expected to grow over the forecast period as a larger patient base adopts these solutions.

Asia Pacific Smart Insulin Pens & Pumps Market Trends

The smart insulin pens & pumps market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The region is experiencing a rapid increase in the prevalence of diabetes. For instance, the IDF Diabetes Atlas has projected a substantial increase in diabetes prevalence in this region between 2021 and 2045. Furthermore, rapid economic growth in China, South Korea, India, and Thailand, rising disposable incomes, and increased government investments in healthcare infrastructure are driving the adoption of advanced medical technologies. This growth is expected to create a substantial demand for innovative insulin-delivery solutions from 2026 to 2033.

According to the IDF (2025), approximately 89.8 million adults aged 20–79 years in India were living with diabetes in 2024, making India the second-largest diabetes population globally after China. This number is expected to increase rapidly owing to the combined effects of changing dietary preferences, a sedentary lifestyle among the urban populace, and rising incidence of prediabetic conditions in children. The Indian government is providing financial and technical support to states for addressing this issue under its National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD). These factors, along with the increasing spending power of the country’s population, have ensured high market potential for smart insulin pens and pumps.

Key Smart Insulin Pens & Pumps Companies Insights

Some key companies involved in the smart insulin pens & pumps industry include Novo Nordisk A/S, Sanofi, and Insulet Corporation, among others.

• Novo Nordisk A/S specializes in developing solutions for diabetes and insulin delivery. The company’s advanced NovoPen 6 and NovoPen Echo Plus automatically record insulin dosing information for each injection, including time, date, and number of units dosed. These pens provide glucose information on mobile apps for better monitoring. Apart from smart diabetes management devices, the company offers other diabetes treatment options tailored to the patients' budgets and needs.
• Insulet Corporation is a U.S.-based medical device company that offers its waterproof smart insulin pumps to over 25 countries worldwide under the brand Omnipod. Omnipod provides continuous insulin delivery for up to 72 hours. The latest Omnipod 5 comes with SmartAdjust technology for customized insulin delivery in patients. In addition, the Omnipod DASH personal diabetes monitor (PDM) is a tubeless, wireless insulin management system that offers convenience and mobility for patients.

Key Smart Insulin Pens & Pumps Companies

The following key companies have been profiled for this study on the global smart insulin pens & pumps market:

• Novo Nordisk A/S

• Sanofi

• Insulet Corporation

• Medtronic

• Abbott

• Lilly

• F. Hoffmann-La Roche Ltd

• Emperra GmbH E-Health Technologies

• YPSOMED

• Tandem Diabetes Care, Inc.

• Cambridge Consultants

• pendiq

• SOOIL Developments Co., Ltd

• DUKADA

• delfu-medical.com

Recent Developments

• In January 2026, Medtronic Diabetes received U.S. FDA clearance for the MiniMed Go Smart MDI system, a connected diabetes management solution that integrates the InPen smart insulin pen with Abbott's Instinct continuous glucose monitoring (CGM) sensor through the MiniMed Go™ app. The system delivers real-time glucose insights, personalized dose calculations, missed dose reminders, and decision support, enhancing diabetes management and reinforcing the growing adoption of connected smart insulin pens and integrated insulin delivery solutions.

• In August 2025, Abbott and Medtronic announced a global partnership to develop an integrated continuous glucose monitoring (CGM) solution based on Abbott's FreeStyle Libre technology for compatibility with Medtronic's automated insulin delivery systems and smart insulin pens. The collaboration is expected to improve diabetes management by combining continuous glucose monitoring with advanced insulin delivery technologies, supporting innovation and accelerating the adoption of connected smart insulin solutions worldwide.

• In June 2024, Novo Nordisk announced its plan to invest around USD 4.1 billion to build a manufacturing facility in North Carolina, and to grow its capacity to produce injectable treatments for patients suffering with obesity and other chronic disorders.

Global Smart Insulin Pens & Pumps Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global smart insulin pens & pumps market report based on type, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Smart Insulin Pens

    • Companion Medical (InPen)

    • Novo Nordisk (NovoPen 6 & NovoPen Echo)

    • Emperra Gmbh (ESYSTA Pen)

    • pendiq intelligent diabetes care (pendiq 2.0)

    • Others

  • Smart Insulin Pumps

    • MiniMed (630G and 670G)

    • Accu-Chek (Combo and Insight)

    • Tandem (t: slim X2, t: slim G4)

    • Insulet (Omnipod)

    • myLife Omnipod

    • Others

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals and Clinics

  • Homecare

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • India

    • China

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait